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aims: Recent studies indicate that anti-inflammatory drugs, act as a double-edged 
sword, not only exacerbating secondary brain injury but also contributing to neurological 
recovery after stroke. Our aim is to explore whether there is a beneficial role for neuropro-
tection and functional recovery using anti-inflammatory drug along with neurorehabilita-
tion therapy using transcranial direct current stimulation (tDCS) and repetitive transcranial 
magnetic stimulation (rTMS), so as to improve functional recovery after ischemic stroke.
Methods: We develop a computational systems biology approach from preclinical 
data, using ordinary differential equations, to study the behavior of both phenotypes 
of microglia, such as M1 type (pro-inflammatory) vis-à-vis M2 type (anti-inflammatory) 
under anti-inflammatory drug action (minocycline). We explore whether pharmacological 
treatment along with cerebral stimulation using tDCS and rTMS is beneficial or not. We 
utilize the systems pathway analysis of minocycline in nuclear factor kappa beta (NF-
κB) signaling and neurorehabilitation therapy using tDCS and rTMS that act through 
brain-derived neurotrophic factor (BDNF) and tropomyosin-related kinase B (TrkB)
signaling pathways.
results: We demarcate the role of neuroinflammation and immunomodulation in post-
stroke recovery, under minocycline activated-microglia and neuroprotection together 
with improved neurogenesis, synaptogenesis, and functional recovery under the 
action of rTMS or tDCS. We elucidate the feasibility of utilizing rTMS/tDCS to increase 
neuroprotection across the reperfusion stage during minocycline administration. We 
delineate that the signaling pathways of minocycline by modulation of inflammatory 
genes in NF-κB and proteins activated by tDCS and rTMS through BDNF, TrkB, and 
calmodulin kinase (CaMK) signaling. Utilizing systems biology approach, we show that 
the activation pathways for pharmacotherapy (minocycline) and neurorehabilitation 
(rTMS applied to ipsilesional cortex and tDCS) results into increased neuronal and 
synaptic activity that commonly occur through activation of N-methyl-d-aspartate 
receptors. We construe that considerable additive neuroprotection effect would be 
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inTrODUcTiOn
Recent investigations have reported that immune responses to 
inflammation are non-specific systemic infections associated 
with progression of neurodegenerative diseases via activation 
of macrophages (1). Minocycline is a tetracycline antibiotic 
having several properties, such as anti-inflammatory, anti-
apoptosis, free radical scavenger, and protein misfolding (2). 
The therapeutic effects of minocycline in preclinical models of 
neurodegenerative diseases showed direct neuroprotection and 
reduction of microglial inflammatory responses (3). It has been 
reported in in vivo studies that minocycline blocks the adhesion 
of leukocytes to cerebrovascular endothelial cells induced by 
lipopolysaccharides, as well as tumor necrosis factor-α (TNF-α) 
production in the brain (4). In vitro studies have reported the 
anti-inflammatory effects of minocycline for neuroprotection (5) 
and in macrophages (6). Neuroprotective effects of minocycline 
include reduction of macrophage activation, prevention of the 
potentiation of ischemia-like injury to astrocytes and endothelial 
cells consolidating the brain tissue parenchyma (7). Although, 
the anti-inflammatory effects of minocycline are known to some 
extent, the direct effects of neuroprotection have not been well 
investigated in neurodegenerative diseases.
Several studies have shown that the physiological neuro-
protection mechanisms that occur after stroke are targeted 
through various signaling pathways. Several studies suggest 
that the mechanisms associated with either reducing the size of 
infarct or enabling neurorestoration, involve the following enti-
ties: (i) anti-high mobility group box-1 activity (8); (ii) NF-κB 
(9); (iii) mammalian target of rapamycin (mTOR) inhibitor 
(10, 11); (iv) stimulation of toll-like receptors (TLR2 and 
TLR4) prior to brain ischemia (12, 13), (v) c-Jun N-terminal 
kinase (JNK) inhibitor (14); (vi) p38 mitogen-activated protein 
kinase (p38 MAPK) inhibitor (15); (vii) MEK1 pathway (16); 
(viii) MAPP/MEK/ERK inhibitor (17); and (ix) Minocycline-
induced reduction of LPS-stimulated p38 MAPK activation, 
and stimulation of the phosphoinositide 3-kinase (PI3K)/Akt 
pathway (18).
Currently, little is known about endogenous counter regula-
tory immune mechanisms that can induce neurorestoration. The 
glycogen synthase kinase-3β (AKT/GSK-3β) pathway has been 
recognized as a protective pathway against cerebral ischemic 
injury. In cerebral ischemia models, it has been shown that 
remote limb conditioning does indeed activate and upregulate 
the pro-survival AKT pathway (19) and long-term protection 
against cerebral ischemia is afforded by limb post-conditioning 
that is associated with AKT, MAPK, phosphatidylinositol 
3-kinase (PI3K), and protein kinase C (PKC) signaling pathways 
(20). NF-κB transcription factor family members, such as p50, 
p65/RelA in the hippocampus, are regulated by metabotropic 
glutamate receptor signaling and c-Rel transcription factor is 
responsible for the formation and maintenance of long-term 
memory (21). Minocycline directly inhibits matrix metallo-
proteinase (MMP)-9 activation through NF-κB pathway (22). 
In  silico modeling of anti-inflammatory response has been 
reported for endotoxins (LPS) and corticosteroids by activating 
TLRs in NF-κB (23).
Taken together, the modulation of cell survival and death 
signaling by hypoxic/ischemic preconditioning appears to be 
capable of targeting multiple levels of signaling cascades. Several 
inhibitors targeted the point of convergence through distinct and 
interacting signaling pathways (crosstalk mechanism) for inflam-
mation by activating macrophages that lead to neuroprotection. 
Also, cerebral stimulation-based transcranial magnetic stimula-
tion and direct current stimulation enhances brain-derived 
neurotrophic factor (BDNF) and tropomyosin-related kinase B 
(TrkB) signaling (24, 25). In this study, we harness the convergent 
signaling pathways of pharmacotherapy (anti-inflammatory, 
immunomodulatory) and neurorehabilitation therapy (func-
tional recovery) for efficient post-stroke neurorestoration by 
experimental and systems-level approach. We modeled using 
the systems biology approach of minocycline modulation of 
MMPs through NF-κB signaling pathway, a master regulator of 
inflammatory responses along with neurorehabilitation-based 
activation in BDNF and TrkB signaling.
MaTerials anD MeThODs
There are numerous cellular responses, stress events, neuronal 
death, and inflammatory mechanisms, including over-activation 
of microglia as shown in Figure  1. We utilized and targeted 
anti-inflammatory drug in our approach. We formulated 
various cell kinetics interactions utilizing the systems biology 
platform for pharmacotherapy (Module 1) and neurorehabilita-
tion (Module 2)-based activation through different signaling 
pathways, such as NF-κB, BDNF, and TrkB. To formulate and 
obtained and delayed reperfusion injury can be remedied, if one uses multimodal 
intervention of minocycline together with tDCS and rTMS.
conclusion: Additive beneficial effect is, thus, noticed for pharmacotherapy along with 
neurorehabilitation therapy, by maneuvering the dynamics of immunomodulation using 
anti-inflammatory drug and cerebral stimulation for augmenting the functional recovery 
after stroke, which may engender clinical applicability for enhancing plasticity, rehabilita-
tion, and neurorestoration.
Keywords: stroke, neuroprotection, rehabilitation, minocycline, direct current stimulation, transcranial magnetic 
stimulation
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model the effect of therapeutic interventions, we activated 
the corresponding signal transduction factor accordingly. For 
minocycline, activation input was in the form of a constant 
single impulse or step function, while for the transcranial 
direct current stimulation (tDCS) and repetitive transcranial 
magnetic stimulation (rTMS) inputs, we used repeated series 
of electrical or magnetic pulses involved in cerebral stimula-
tion. The chemical reactions of the modules were constructed 
using the framework of ordinary differential equations (ODEs), 
which were then solved by numerical computation using the 
Runge–Kutta method.
Pharmacotherapy (Minocycline) through 
nF-κB signaling Pathway
We formulated and elucidated the cascade of cell signaling 
events using ODEs that were solved using ODE23 solver in 
MatlabR2013a. We modeled the inflammatory mechanism of 
minocycline through regulation of genes and proteins that 
significantly corresponded to NF-κB transcriptome as shown 
in Figure 2. Studies have suggested that minocycline-induced 
suppression of NF-κB activity is mediated by the inhibition 
of M1 microglia and activation of M2 microglia. All the 
sequential chemical processes are explained in Module 1. The 
in  vitro and in  vivo studies have shown that both the acute 
and chronic doses of minocycline lead to suppression of p65 
phosphorylation and nuclear translocation accompanied by 
downregulation of NF-κB activity and endogenous MMP9 
protein levels (22).
Using the dynamics of known NF-κB stages (26, 27), the action 
of minocycline via the signaling pathway was represented as 
shown in Module 1. The sequence depicts a chronological order 
of the formation of different biochemical species (mentioned on 
the right side after % symbol) with their corresponding reaction 
kinetic equation (on the left side).
The non-zero initial concentration of the chemical species and 
the association and dissociation rate constants are taken from 
previous experiments (23, 26) given in APPENDIX (Table A1). 
The ODE equations shown in Module 1 were solved using ODE23 
solver in MatlabR2013a.
neurorehabilitation Therapy through BDnF 
and TrkB signaling Pathway
To elucidate the process of neurorehabilitation therapy using 
tDCS and rTMS via BDNF and TrkB pathway. We constructed 
the upstream and downstream dynamics of the pathway using 
currently available data (28). The corresponding chemical reac-
tions are formulated as ODE and shown in Module 2.
Cerebral Stimulation (rTMS and tDCS) through  
BDNF and TrKB
Brain-derived neurotrophic factor activates TrkB through several 
downstream signaling pathways, such as AKT, CaMK, Ras/Raf/
MEK/ERK leading to cell survival, growth, and neuroplasticity 
as shown in Figure  3. BDNF activates TrkB stimulation via 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) and 
also activates proteins like Shc, Grb-2, and Gab-1. The PI3K 
is also activated by binding to Ras homolog enriched by brain 
glutamine triphosphate (Ras-GTP). TMS was delivered to male 
Sprague Dawley rats using 1600 stimuli at 5 Hz in four blocks of 
each 400 stimuli in 2.5 min with 1 min inter-block interval (24). 
FigUre 1 | cascade of cell signaling events post-stroke and enabling neuroprotection using minocycline.
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Anodal tDCS was applied with current density of 0.04 mA/cm2, 
total charge of 0.048 C/cm2 for 20 min (25). Activated PI3K phos-
phorylates PtdIns[3,4]P2 (PIP2) and PtdIns[3,4,5] P3 (PIP3), 
and then PIP3 is dephosphorylated by phosphotase and tensin 
homolog (PTEN). PIP3 activates AKT (also known as protein 
kinase B) leading to the formation of Rheb-GTP, a regulator of 
rapamycin (TOR) (29, 30). AKT needs phosphorylation twice to 
become active. PIP3 binds to AKT and recruits it in the mem-
brane and does the same for Pyruvate dehydrogenase lipoamide 
kinase isozyme 1 (PDK1).
In the membrane, PDK1–PIP3 complex phosphorylates AKT 
on Thr308 and further phosphorylates on Ser-473 by PIP3-PDK2. 
Both these phosphorylates are reversed by protein phosphatase 
2A (PP2A). The doubly phosphorylated AKT becomes active and 
phosphorylates tuberous sclerosis 1,2 (TSC1–TSC2), which in 
turn regulates Rheb-GTP levels. The unphosphorylated complex 
has GTPase-activating protein (GAP)-type properties toward 
Rheb, while TSC1–TSC2 hydrolyzes Rheb-GTP to Rheb-GDP 
(31). The active AKT inactivates TSC1–TSC2 and only Rheb-
GTP remains. Therefore, the net effect is, PIP3 activates AKT 
leading to activation of downstream target TOR. Furthermore, 
Rheb-GTP activates TOR and the converged input from MAPK 
leads to S6K activation, forming active 40S for translation (32, 33). 
The Rheb-GTP binds to the TOR_complex to stimulate kinase 
activity through phosphorylation in each kinase, viz. MAPK, 
TOR_complex, and PDK1. Next, dephosphorylation occurs at all 
the sites by PP2A. The double- and triple-phosphorylated S6K 
becomes active and phosphorylates S6, which is a subunit of 40S 
ribosomal protein.
Another possible signaling mechanism is phospholipase 
C gamma (PLC-γ) that in turn cleaves PIP2, diacylglycerol 
(DAG), and inositol trisphosphate (IP3). DAG remains bound 
to membrane, whereas IP3 is released as a soluble structure 
into the cytosol. Then IP3 diffuses through cytosol and binds 
to IP3 receptors, particularly calcium channels in a smooth 
endoplasmic reticulum, and then activates Ca2+ in calmodulin 
kinase (CaMK) activity. Correspondingly, DAG activates PKC 
for plasticity (34). CaMKIII is activated by Ca2+ and inactivated 
by S6K. CaMKIII inhibits eukaryotic elongation factor 2 (eEF2), 
the net effect of Ca2+ on elongation factor is inhibitory and of S6K 
is excitatory. eEF2 is the major substrate for CaMKIII. CaMKIII 
catalyzes eEF2 phosphorylation at thr-56 and thr-58, strictly in 
the presence of Ca2+ and CaM (35). CaMKIII phosphorylates 
eEF2 to render it inactive. Dephosphorylation of eEF2 by PP2A 
restores its activity.
The S6K phosphorylates CaMKIII at Ser-366 and decreases its 
activity and thereby increases the level of eEF2 (36). Calmodulin 
dependence of CaMKIII activity was measured in terms of eEF2 
phosphorylation (37). Next, the active S6K is added to CaMKIII 
and time course of CaMKIII is measured. Then, active eEF2-
thr-36 is measured with respect to time. The dose–response for 
40S complex is measured for different 40S concentrations (38), 
the dephosphorylation reaction and the formation of phospho-
rylated eEF2 (28). The 40S and eEF2 bind to form the translation 
complex, leading to protein synthesis. MAPK is downstream of 
PI3K as well as CaM-Ca4. The MAPK activity is closely related to 
synaptic activity leading to Ca2+ influx. The alternate mechanism 
is through downstream signaling of Ras/Raf/MEK/ERK pathway 
for cell survival, growth, and neuroplasticity.
The non-zero initial concentration of chemical species is given 
in APPENDIX (Table A2). All these parameters are taken from 
the experimental studies related to memory, learning, and synap-
tic plasticity through BDNF and TrkB signaling. The implications 
of tDCS and rTMS in the present study are to enhance the post-
stroke motor-learning along with functional recovery in ischemic 
stroke patients. The association and dissociation rate constants 
are taken from experimental studies as given in APPENDIX 
(Table A3). The aforesaid equations are given in Module 2, which 
were solved by ODE23 solver in MatlabR2013a.
resUlTs
We simulated the biochemical processes of both Modules 1 and 2. 
Our observations and inferences are explained in details below.
Pharmacotherapy (Minocycline)
The results of the signaling activation by the pharmacological agent 
minocycline are shown in Figure 4. A sub-optimal dose of 4.5 mg 
kg−1 was chosen from a dose escalation study of minocycline in 
stroke patients (81). Our findings delineate the inflammatory 
mechanism of minocycline through regulation of genes and pro-
teins that correspond to the NF-κB transcriptome. Our simulation 
has shown the molecular mechanism of minocycline that could 
be attributed to modulation of NF-κB signaling. Minocycline 
suppressed NF-κB activation in neurons and glial cells and was 
correlated with attenuation of IκBα kinase (IKK) activation, IκBα 
phosphorylation and degradation, and p65 phosphorylation and 
nuclear translocation. The inhibition of IKK was found to be 
associated with suppression of activated-microglia (neurotoxic 
M1 microglia) and correspondingly enhanced the restorative 
microglia (neuroprotective M2 microglia). Furthermore, the 
simulation demonstrated that minocycline upregulated TNF-α 
expression. Enforced TNF-α expression induced NF-κB activity 
and minocycline rescued through inhibition of iNOS and NO 
production in cells. Our simulated results are consistent with 
the experimental findings that suppressed NF-κB activation and 
abrogated the inhibitory effect of minocycline on the transcrip-
tion factor, TNF-α. These results suggest that minocycline led to 
suppression of p65 phosphorylation and nuclear translocation 
accompanied by downregulation of NF-κB activity and endog-
enous MMP9 protein levels and its target, PTGS2 gene.
In the simulation, a minocycline dose of 4.5 mg kg−1 induced 
TNF-α activity for 6 h as shown in Figure 4A. The neutral IKK 
activity gradually reduced from 60 to 90 min and then asymp-
totically saturated downwards to baseline as shown in Figure 4B. 
Similarly, the inactive form of IKK increased from 60 to 90 min 
and then saturated to baseline as shown in Figure 4C. The active 
IKK expression increased from 60 to 90 min, peaked at 90 min and 
then fell gradually till 120 min and saturated downwards to basal 
level as shown in Figure  4D. Free cytoplasmic IκBα increased 
from 60 to 90 min, peaked at 120 min and then gradually fell till 
180 min and oscillated as shown in Figure 4E. The cytoplasmic 
IκBα|NF-κB activity initially fell till 60  min, then peaked at 
120  min, fell down till 180  min, and then showed oscillatory 
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behavior as shown in Figure 4F. The free nuclear IκBα increased 
from 60 to 140 min, fell down till 180 min and finally damped 
as in Figure 4G. The free nuclear NF-κB activity increased from 
60 to 90 min, fell down from 90 to 120 min, and then showed 
oscillatory behavior as in Figure 4H.
The PTGS2 gene transcription increased from 60 to 120 min, 
fell down till 180 min, and then oscillated as shown in Figure 4I. 
The expression of IKKa|IκBα complex increased from 60 to 
90  min, gradually fell till 180  min, and then oscillated as in 
Figure 4J. The expression of IKKa|IκBα|NF-κB complex peaked 
at 60 min and then fell afterwards as shown in Figure 4K. The 
nuclear IκBα|NF-κB expression increased from 60 to 120  min 
and then gradually fell till 180 min and oscillated as in Figure 4L. 
Free and phosphorylated IκBα bounded to cytoplasmic NF-κB 
FigUre 2 | Minocycline-activated anti-inflammatory response through nF-κB signaling pathway.
6Alam et al. In Silico Modeling of Multimodal Therapy for Stroke
Frontiers in Neurology | www.frontiersin.org June 2016 | Volume 7 | Article 94
peaked at 60  min, fell gradually till 90  min and damped as in 
Figure 4M. Free cytoplasmic IκBα expression increased from 60 
to 120 min then gradually fell till 180 min, and finally oscillated 
as in Figure  4N. The total cytoplasmic IκBα activity initially 
fell down till 60  min and then onward gradually increased 
till 120  min, and finally showed oscillatory behavior as in 
Figure 4O. It is important to note that the temporal profile for 
the chemical species will not change for different concentrations 
of minocycline.
neurorehabilitation Therapy Using tDcs 
and rTMs
The simulations showed increased activity of TrkB*2 from 0 to 
500 s, and then fell till 1000 s, and then asymptotically saturated 
downwards to a definitive level as shown in Figure 5A. The Shc* 
activity increased linearly when plotted against BDNF till the 
BDNF concentration reached 2 nM as shown in Figure 5B. The 
PLC-γ activity increased linearly when plotted against BDNF till 
the concentration of 3.7 nM as in Figure 5C. Furthermore, the 
PIP3 activity linearly increased as shown in Figure  5D, while 
the cell elongation factor (eEF2) eEF2thr-56 showed sigmoid 
relationship when plotted against low concentrations of the 
calcium-binding protein Calmodulin, CaM (measured in terms 
of negative log) as in Figure 5E. eEF2 activity was observed to 
linearly increase with time as in Figure  5F. We observed that 
40S complex activity displayed a declining sigmoidal function 
with an increased activity till 300 nM when plotted against 40S 
concentration, followed by constant activity (very slowly declin-
ing) from 300 to 600 nM, and thereafter finally the activity rises 
beyond 600 nM as in Figure 5G.
Continuing the formulation further, we note that the kinase 
CaMKIII activity increased till 240 s and then saturated upwards 
as shown in Figure 5H. We found active AKT increase till 100 s, 
decreased after 480 s and then downward saturation to baseline 
as in Figure 5I. We inferred that the BDNF synthesis rate was 
maximum for the concentration of 3.7 nM as shown in Figure 5J. 
Moreover, we noticed eEF2 synthesis rate linearly increased when 
plotted against eEF2 concentration, for both basal kinase activity 
and for BDNF concentration of 3.7 nM (Figure 5K). We found 
that the synthesis rate of eEF2 for BDNF concentration of 3.7 nM 
was double the basal kinase level, when the eEF2 concentration 
is 5 nM as shown in Figure 5K. We also showed that the 40S syn-
thesis rate peaked at 500 nM of 40S concentration for both basal 
kinase level and for BDNF level of 3.7 nM, and 40S synthesis rate 
was higher for BDNF level of 3.7 nM than that for basal kinase 
level, as shown in Figure 5L.
We also found that protein synthesis rate is constant for 
all BDNF concentrations for Ca2+  =  0.5  nM and notice that 
increase of synthesis rate occurs beyond 0.1 nM concentration 
for Ca2+ =  0.08  nM. This suggests that BDNF =  3.7  nM and 
lower Ca2+ concentration leads to higher protein synthesis rate 
as shown in Figure  6A. We plotted the percentage of kinase 
enzymes CaMKIII and MAPK activity against Ca2+ concentra-
tion and found MAPK activity peaked for Ca2+ = 0.5 nM, while 
CaMK activity peaked for Ca2+ = 1.0 nM as shown in Figure 6B. 
The protein synthesis rate for constant CamKIII = 0.6 μM gradu-
ally decreased for both basal kinase activity and for BDNF level 
of 3.7 nM, till Ca2+ = 0.1 μM. Thereafter, the protein synthesis 
activity was constant for higher Ca2+ concentrations. However, 
the synthesis rate was initially higher for BDNF level of 3.7 nM 
than for basal kinase activity, for lower values of Ca2+ concentra-
tion (<0.1 μM), as in Figure 6C.
As mentioned earlier, we activated the corresponding signal 
transduction factor accordingly (inositol triphosphate IP3, and 
the related compound, phosphatidyl-IP3, viz. PIP3). First, the 
initial activation of IP3 through phospholipase C (PLC-γ) and the 
activation of PIP3 through PI3K were plotted for TMS and DCS. 
TMS showed higher level of IP3 than PIP3 with higher number 
of reactant molecules generated till 150 s, and then the number 
of molecules saturated to a definitive level as in Figure 6D. DCS 
showed higher PIP3 than IP3 with an increased number of mol-
ecules till 150 s as in Figure 6E.
Thus, we have shown that both TMS and DCS activated 
CaMKIII that shows the cell survival and synaptic plasticity. 
To draw a perspective, we elucidated that all the modalities 
(minocycline, tDCS, rTMS) have different pathways with com-
mon activation of N-methyl-d-aspartate (NMDA) receptors. 
Therefore, pharmacotherapy and neurorehabilitation can be 
incisively combined for additive beneficial effect.
DiscUssiOn
Oxidative stress and inflammation are the two major patho-
physiological mechanisms involved during early and late phases 
of ischemic stroke. Brain tissue is not armed with antioxidant 
defenses, so reactive oxygen species and other free radicals/oxi-
dants released by inflammatory cells, threaten tissue viability in 
the core ischemic region. This study targets the molecular aspects 
of inflammation in ischemic stroke and offers potential therapeu-
tic strategies that target neuroinflammation and modulates the 
innate immune system. In addition to antibiotic activity, mino-
cycline exhibits anti-inflammatory responses in both monocytes 
and macrophages. Earlier studies have reported that minocycline 
causes significant reduction in the inflammatory response of 
LPS-challenged monocytes, reducing LPS-induced transcription 
of pro-inflammatory TNF-α, interleukin-1 beta (IL-1β) (82), 
interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2) (83), the 
LPS stimulated TNF-α, IL-6, and PGE2 release. Minocycline 
inhibited LPS-induced activation of the lectin-like oxidized low-
density lipoprotein receptor-1 (LOX-1), NF-κB, LPS-induced 
TNF-α factor (LITAF) and the Nur77 nuclear receptor (20). It has 
been reported that the neuroprotective effects of minocycline are 
associated with inhibition of iNOS induction and NO production 
in glial cells, which are mediated by the LPS-induced production 
of TNF-α (84).
Pharmacotherapy: Minocycline
The regulation of inflammatory genes and proteins in NF-κB 
signaling pathway are MMPs and Cox-2. MMPs are a family 
of zinc-dependent proteases responsible for the degradation of 
extracellular matrix proteins and capable of causing bioactive 
molecules. Cox-2 inhibitors are non-steroidal anti-inflammatory 
drugs (NSAIDs). The in vitro models showed direct neuroprotec-
tion by minocycline as well as inhibition of other inflammatory 
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mediators, such as iNOS, MMPs, TNF-α, and tissue plasminogen 
activator (tPA). However, some earlier studies have reported 
expression of inflammatory cytokines, such as TNF-α in ischemic 
neurons (85) and tPA (86), and generation of neuronal tPA has 
been thought to mediate microglial activation. Thus, these studies 
suggested that neurons may be capable of secreting inflamma-
tory mediators themselves from classical immune cells, includ-
ing microglia and other glial cells, such as astrocytes. Also the 
neuronal survival depends on the endogenous or exogenous tPA, 
which can be either neuroprotective or neurotoxic. Similar conclu-
sions could be made of neuronal generation of iNOS and MMPs. 
MMPs 2 and 9 levels are elevated a few hours after ischemia (87) 
and maintain increased activity for days after the onset of stroke 
(88). The specific class of agents inhibits these enzymes, reverts 
the breakdown of laminin (89), and prevents increased barrier 
permeability, edema, and hemorrhage after ischemic stroke (90).
Ischemic stroke activates a complex cascade of events and 
tetracycline antibiotics may exert anti-inflammatory effects by 
multiple mechanisms. The models of brain injury, which involve 
matrix degradation and vascular instability, targets inhibition of 
proteolytic cascade. However, there are limitations for the usage 
of MMP inhibitors as therapeutic agents because of their poor 
solubility. Minocycline has been shown to be a neuroprotective 
agent by inhibiting MMP2 and MMP9 activation by ischemia 
(91). The dysregulation of the proteolytic cascade at the level 
of the endothelial and microglial cells is one of the common 
pathological mechanisms of ischemic brain damage. Minocycline 
targets through the interference of this cascade and might be the 
key pathway for neuroprotection and salvage of injured tissue. 
Animal models of permanent cerebral ischemia showed that 
minocycline treatment was protective and beneficial in cerebral 
ischemia by mechanisms that are not linked to the production 
of free radicals during reperfusion. Understanding inflamma-
tory interactions of all brain cell types is needed to identify how 
they may be manipulated to provide neuroprotection. Studies of 
minocycline effects on brain cells in addition to microglia are 
FigUre 3 | BDnF and TrkB signaling pathway.
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timely, as minocycline has shown efficacy in clinical studies for 
various neurodegenerative disorders (92, 93) and ischemic stroke 
(81, 94, 95). Thus, further investigations are needed for a better 
understanding of the complexities of immune responses of vari-
ous types of cell bodies following brain injury.
Direct current stimulation
The primary mechanism of tDCS for inducing cortical excit-
ability shifts is a sub-threshold modulation of the neuronal 
resting membrane potential. The anodal stimulation outcome 
is a sub-threshold depolarization, while cathodal stimulation 
hyperpolarizes neuronal membranes. During a short tDCS, 
which elicits no after-effects (stimulation duration of about 4 s), 
synaptic mechanisms are not involved, as shown by the absence 
of effect of NMDA receptor antagonists, the GABA agonist 
lorazepam and the monoamine reuptake blocker amphetamine 
on the tDCS-induced excitability changes under these condi-
tions. Furthermore, the after-effects are not due to reverberating 
electrical circuits or other purely electrical phenomena, as shown 
in early animal experiments. They depend on modifications of 
NMDA receptor efficacy, since these are blocked by the NMDA 
receptor antagonist dextromethorphan, but prolonged by the 
partial NMDA receptor agonist d-cycloserine (96). The tDCS 
polarity-dependent shift of NMDA receptor function seems 
to be initiated by the respective membrane potential shift and 
probably by the accompanying cortical activity modification, 
because it is prevented by the sodium channel blocker (carba-
mazepine). Likewise, tDCS requires the neurophysiological 
experimental studies for the selection of electrode montage in 
stroke (97). Furthermore, in silico modeling studies are required 
to understand the neuromodulatory effects of tDCS and helps in 
determining the optimal levels of anodal and cathodal stimula-
tion that is beneficial for stroke patients.
Earlier studies also reported a decrease in IP 3 receptor mRNA 
level in the cortex at 4 h after a 45 min ischemic insult; however, 
lesser change was noticed for IP3 3-kinase mRNA levels during 
the initial 8 h after reperfusion (98). Also, IP3 receptor mRNA 
level in the peri-infarct areas was also reduced, specifically at a 
delayed time of reperfusion. The staining of cortical neurons in 
the infarct area showed morphological changes between 4 and 8 h 
after reperfusion (99). Thus, the decrease in IP3 receptor mRNA 
level probably occurred at a time prior to alteration of neuron 
morphology. A recent study showed that DCS stimulation-
induced vasodilation occurs without IP3 receptor activation (100).
Brain-derived neurotrophic factor induces the transformation 
of early- to late-phase long-term potentiation (LTP) in the pres-
ence of protein synthesis inhibitors and BDNF–TrkB signaling is 
involved in synaptic tagging (101). BDNF activates the RAS/RAF 
signaling pathway and produces ERK, promoting gene transcrip-
tion through cAMP-response element binding protein (CREB) 
in the cell nucleus. NMDA activation on the cell membrane 
produces a calcium influx that activates calcium CaMK IV, phos-
phorylating glycogen synthase kinase 3B (GSK3B) and allowing 
B-catenin to activate CREB. Recent studies have provided differ-
ent mechanistic explanation for the early and late phases of LTP. 
The mechanism for later phases of LTP required for memory stor-
age is the complex of CaMK signaling with the NMDA receptor 
(102). Furthermore, neurophysiological and in  silico modeling 
studies are required to understand the neuromodulating effects 
of tDCS, and help in determining the optimal levels of anodal and 
cathodal stimulation that is beneficial for stroke patients.
Transcranial Magnetic stimulation
Earlier study have reported the effects of rTMS and illustrated 
the mechanisms of rTMS in regulating cognitive capacity. rTMS 
enhances spatial memory behavior, neuron and synapse mor-
phology in the hippocampus, and synaptic protein markers and 
BDNF/TrkB in normal aging mice (103). Aging mice inhibited 
the activation of BDNF–TrkB signaling pathway and showed 
hippocampal-dependent cognitive impairment in relative to 
adult animals, with the reduced transcription and expression of 
synaptic protein markers, such as growth-associated protein 43 
(GAP43), synaptophysin (SYN), post-synaptic density protein 95 
(PSD95), including decreased synapse density, and PSD thick-
ness. Surprisingly, low-intensity rTMS (110% average resting 
motor threshold intensity, 1 Hz) triggered the activation of BDNF 
and TrkB, upregulated the level of synaptic protein markers, 
increased synapse density and PSD thickness, and reversed the 
spatial cognition dysfunction in aging mice. On the other hand, 
high-intensity rTMS (150% average resting motor threshold 
intensity, 1 Hz) was harmful, inducing reduction of PSDs thick-
ness, disordered synaptic structure, as well as reduction in the 
number of synapses, and downregulation of BDNF–TrkB and 
synaptic proteins. The aging-induced cognitive deficits depends 
on the intensity level of TMS, which are closely associated with 
hippocampal structural synaptic plasticity that plays an impor-
tant role in regulating cognitive behavior via changing structural 
synaptic plasticity through BDNF signaling. The effect of rTMS 
on functional recovery and its underlying molecular mechanism 
has been studied by assessing proteins associated with neural 
plasticity in a sub-acute ischemic rat model (104). A total of 3,500 
impulses with 10 Hz frequency were applied to the ipsilesional 
cortex from post-operative day 4 over a 2-week period. The study 
reported that rTMS group showed more functional improve-
ment on the beam balance test and the immunohistochemistry 
analysis showed stronger Bcl-2 and weaker Bax expression when 
compared with the sham group and noticed no significant differ-
ence in the expressions of NMDA and MAP-2 (104). However, 
rTMS may increase or decrease motor cortical excitability mostly 
depending on the characteristics of the stimulation protocol 
(105). Non-invasive cortical stimulation upregulates excitability 
in M1 lesioned hemisphere and downregulates in M1 intact 
hemisphere that could contribute to correcting abnormalities in 
inter-hemispheric inhibition identified after stroke (106). Thus, 
both the pharmacotherapy and neurorehabilitation therapy 
converge through the NMDA receptor activation.
One of the challenges for antibiotic therapy is the need to 
identify the optimum dose level. Recently, a reliable and feasible 
approach of dose estimation using chemical binding kinetics was 
proposed by Abel et al. (107). Another challenge is determining 
the impact of combinational multiple drug therapies on several 
proteins. A recent study suggested an approach using linear super-
position of their responses to individual therapy (108). Utilizing 
these approaches, we can develop in silico models that could provide 
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FigUre 4 | Minocycline-induced TnF-α activity in nF-κB pathway.
FigUre 5 | cerebral stimulation induced BDnF and TrkB signaling.
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insight into the design of clinical trials of immunomodulatory 
therapies, ranging from optimal patient-specific dose  selection, 
and duration of proposed therapeutic interventions (109).
cOnclUsiOn
In this paper, we utilize a systems biology approach to maneuver 
the dynamics of immunomodulation using linear combination 
of doses of pharmacotherapy (minocycline) in NF-κB signaling 
pathway along with adjuvant neurorehabilitation therapy (rTMS 
or tDCS) through BDNF and TrkB signaling pathway stimula-
tion for enhancing synaptic plasticity, rehabilitation, and neu-
rorestoration. Thus, a thorough understanding and modeling of 
pathways, along with the optimal therapeutic doses could lead us 
to prevent cell death at an earlier stage and with a higher chance 
of maintaining the long-term viability of the cell protection 
after stroke. To conclude, further studies are required to dissect, 
report, and analyze these pathways toward the goal of improving 
neurorestoration by multimodal therapy for stroke and related 
neurovascular disorders.
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FigUre 6 | cerebral stimulation induced iP3, PiP3, and caMKiii activity.
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aPPenDiX
TaBle a1 | chemical species for Module 1.
x(1) IKKn neutral
x(2) IKKa active
x(3) IKKi inactive
x(4) (IKKa|IkBa)
x(5) (IKKa|IkBa|NFkB)
x(6) NFkB
x(7) NFkBn
x(8) PTGS2
x(9) PTGS2 transcription
x(10) IkBa
x(11) IkBan
x(12) IkBat
x(13) (IkBa|NFkB) cytoplasmic
x(14) (IkBan|NFkBn) nuclear
x(15) Control early gene
TaBle a2 | The following association and dissociation rate constants for 
module i are taken from ref. (23, 26).
constant Description
TN = 0/1 (OFF/ON state) TNF-alpha inactive/active
c1c = 0.00005/100 Inducible transcription (control gene)
c2c = 0 Constitutive transcription (control gene)
c3c = 0.0004 mRNa degradation (control gene)
e1a = 0.0005 IkBa nuclear export Hoff, Fitted
i1a = 0.001 IkBa nuclear import Hoff, Fitted
e2a = 0.01 (IkBa|NFkB) nuclear export, Hoff blue (any short)
i1 = 0.0025 NFkB nuclear import, Hoff blue (short correspond 
to a1)
c1a = AA*0.00005/100 Inducible (linear) IkBa mRNA synthesis, Fitted
c2a = AA*0.000000 Constitutive mRNA IkBasynthesis Fitted
c3a = 0.0004 mRNA IkBa degradation, Fitted
c4a = 0.005*100 IkBa translation rate, Fitted
c5a = 0.0001 IkBa degradation rate, Pando
c6a = 0.00002 (IkBa|NFkB) degradation, Hoff
AA = 1 AA = 1 wild-type cell, AA = 0 IkBa-deficient cell
t1 = 0.1 Degradation of (IKK|IkBa) (any short)
t2 = 0.1 Degradation of (IKK|IkBa|NFkB) (any short)
a1 = 0.5 IkBA*NFkB association Hoff (short, correspond 
to i1)
a2 = 0.2 IKK*IkBa association, Fitted
a3 = 1 IKK*(IkBa|NFkb) association, Fitted
kdeg = 0.000125 Degradation of IKKa, IKKn, and IKKi
kprod = 0.000025 IKKn production rate
r3 = 0.0015 Spontaneous inactivation, Fitted
r2 = 0.1 Inactivation caused by PTGS2, Fitted
r1 = 0.0025 Activation caused by drug, Fitted
c5 = 0.0003 PTGS2 degradation rate, IkBa*5
c4 = 0.005*100 PTGS2 translation rate (Assumed)
c3 = 0.0004 PTGS2 mRNA degradation rate (Assumed)
c2 = AB*0.00000 constitutive PTGS2 mRNA synthesis (Assumed)
c1 = AB*0.00005/100 inducible PTGS2mRNA synthesis (Assumed)
AB = 1 AB = 1 wild-type cell, AB = 0 PTGS2-deficient 
cell
kv = 5 ratio of cytoplasmic to nuclear volume
x13(0) = 0.06 Initial value of NF-κB is given in cytoplasmic 
complex(IkBa|NFkB)
chemical reactions for BDnF and TrKB signaling pathways (Module 2).
y(1) = BDNF + TrKB → BDNF_TrKB_clx % Ligand Binding
y(2) = BDNF_TrKB_clx + TrKB → 
BDNF_TrKB2_clx
% Receptor dimerization
y(3) = BDNF_TrKB2_clx → BDNF_TrKB2*_clx % Autophosphorylation
y(4) = BDNF_TrKB2*_clx ⇒ 
Int_BDNF_TrKB2*_clx
% Receptor Internalization
y(5) = Int_BDNF_TrKB2*_clx → TrKB % Receptor Cycling
y(6) = Shc + BDNF_TrKB2*_clx → BDNF_
TrKB2*_clx + Shc*
% Shc Phosphorylation
y(7) = Shc* → Shc % Dephosphorylation Shc*
y(8) = PLC-γ + BDNF_TrKB2*_clx → BDNF_
TrKB2*_clx + PLC-γ*
% PLC-γ Phosphorylation
y(9) = PLC-γ + PLC-γ_basal → PLC-γ_basal 
+ PLC-γ*
% PLC-γ basal Phosphorylation
y(10) = PLC-γ* → PLC-γ % Dephosphorylation of PLC-γ
y(11) = Grb2 + Shc* → Shc*-Grb2 % Grb2 binding Shc*
y(12) = Shc*-Grb2 + Gab1 → 
Shc*_Grb2_Gab1
% Formation of Shc*_Grb2_Gab1
y(13) = Shc*_Grb2_Gab1 + PI3K → 
Shc*_Grb2_Gab1_PI3K_clx
%PI3K activation by Shc_Grb2_
Gab1 complex
y(14) = Ras-GTP + PI3K → Ras-GTP_PI3K % PI3K activation by Ras-GTP
y(15) = PIP2 + Shc*_Grb2_Gab1_PI3K_clx 
→ Shc*_Grb2_Gab1_PI3K_clx + PIP3
% Formation of PIP3
y(16) = PIP3 + PTEN → PTEN + PIP2 % Formation of PIP2
y(17) = PI3K → PI3K_basal % Formation of basal PIP3
y(18) = PIP2 + PI3K_basal → PI3K_basal % Basal PI3K activity
y(19) = PIP3 + PDK1 → PIP3_PDK1 % PDK1 translocation
y(20) = PIP3 + AKT → PIP3_AKT % AKT translocation
y(21) = PIP3_AKT + PIP3_PDK1 → PIP3_
PDK1 + PIP3_AKT_thr308
% Partial AKT activation (Thr308)
y(22) = PIP3_AKT_thr308 + PP2A → PP2A + 
PIP3_AKT
% Dephosphorylation of AKT*
y(23) = PIP3_AKT_thr308 + PIP3_PDK2 → 
PIP3_PDK2 + PIP3_AKT_t308_s473
%Fully AKT activation (Ser473)
y(24) = PIP3_AKT_t308_s473 + PP2A → 
PIP3_AKT_thr308 + PP2A
% Dephosphorylation of AKT**
y(25) = TSC1–TSC2 + PIP3_AKT_t308_s473 
→ PIP3_AKT_t308_s473 + TSC1–TSC2*
%Phosphorylation of TSC1,2
y(26) = TSC1–TSC2* → TSC1–TSC2 % Dephosphorylation of 
TSC1–TSC2*
y(27) = Rheb-GTP + TSC1–TSC2 → TSC1–
TSC2 + Rheb-GDP
% Hydrolysis of Rheb-GTP by 
TSC1–TSC2
y(28) = Rheb-GDP → Rheb-GTP % Conversion of Rheb-GDP to 
Rheb-GTP
y(29) = IP3R + IP3 → IP3RIP3 % IP3R interaction with IP3 and 
formation of IP3RIP3
y(30) = IP3RIP3 + IP3 → IP3R2IP3 % IP3RIP3interaction with IP3 
and formation of IP3R2IP3
y(31) = IP3R2IP3 + IP3 → IP3R3IP3 %IP3R2IP3interaction with IP3 
and formation of IP3R3IP3
y(32) = IP3R3IP3 + Ca2 → IP3R3IP3 + 
Ca(cyt)
%IP3R3IP3 interaction with 
Ca2+ and formation of IP3R3IP3 
and Ca2+
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y(33) = CaM-Ca4 + CAMKIII → 
CaMKIII_CaM-Ca4
% Binding of Calmodulin-Calcium 
to CaMKIII
y(34) = CaMKIII_CaM-Ca4 + eEF2 → 
eEF2thr-56 + CaMKIII_CaM-Ca4
% Phosphorylation of eEF2
y(35) = eEF2thr-56 + PP2A → eEF2 + PP2A % Dephosphorylation of 
eEF2thr-56
y(36) = CaMKIII + S6K_thr-252 → CaMKIII* +  
S6K_thr-252
% Phosphorylation of CaMKIII
y(37) = CaMKIII + S6K_Basal → CaMKIII* + 
S6K_thr-252
% Basal activation of CaMKIII
TaBle a3 | chemical species and initial concentration for Module 2.
y1(0) BDNF 0.1 nM
y2(0) TrKB 0.25 μM
y3(0) Int_BDNF_TrKB2*_clx 0.25 μM
y6(0) Shc 0.5 μM
y8(0) PLC-γ 0.1 μM
y9(0) PLC-γ_basal 0.0007 μM
y11(0) Grb2 1 μM
y12(0) Gab1 0.7 μM
y13(0) PI3K 0.1 μM
y15(0) PIP2 7 μM
y16(0) PTEN 0.27 μM
y19(0) PDK1 1 μM
y20(0) AKT 0.2 μM
y22(0) PP2A 0.15 μM
y23(0) PIP3_PDK2 0.003 μM
y25(0) TSC1–TSC2 1 μM
y27(0) Rheb-GTP 1 μM 
y29(0) IP3 1 μM
y33(0) CaMKIII 0.06 μM
y34(0) eEF2 0.5 μM
y35(0) PP2A 0.15 μM
y36(0) S6K 0.17 μM
TaBle a4 | The following association and dissociation rate constants 
for Module 2 are taken from ref. (29–33, 37, 39–80).
BD = 0 (BDNF inactive)BD = 1 (BDNF active)
TR = 0 (TrkB inactive)
TR = 1 (TrkB active)
k1f = 1; k1b = 0.05
k2f = 1; k2b = 0.02
k3f = 0.02; k3b = 0
k4f = 0.01; k4b = 0
k5f = 0.001; k5b = 0.001
k6f = 0.8333; k6b = 0.3
k7f = 0.2; k7b = 0
k8f = 0.3; k8b = 0.5
k9f = 0.3; k9b = 0.5
k10f = 0.07; k10b = 0
k11f = 1; k11b = 1 
k12f = 0.3; k12b = 1 
k13f = 5; k13b = 0.08 
k14f = 1.8; k14b = 5
k15f = 4; k15b = 4 
k16f = 0.08; k16b = 5.5
k17f = 0.00068; k17b = 0.45
k18f = 4; k18b = 4
k19f = 0.7; k19b = 0.98
k20f = 45; k20b = 0.089
k21f = 0.4; k21b = 10
k22f = 4.8; k22b = 1.8 
k23f = 0.8; k23b = 20
k24f = 4.8; k24b = 1.8
k25f = 10.3; k25b = 6 
k26f = 0.01; k26b = 0
k27f = 0.3; k27b = 20
k28f = 0.2; k28b = 0
k29f = 100; k29b = 3
k30f = 100; k30b = 2
k31f = 100; k31b = 1
k32f = 100; k32b = 0.1
k33f = 0.99; k29b = 0.09
k34f = 2; k30b = 10
k35f = 8.8; k31b = 0.47
k36f = 1; k32b = 1
k37f = 1; k33b = 10
CaCyt = 0.1
Ca = 0.5
eCAMKIII = 0.06
S6K_thr = 0.001
S6K_Basal = 0.001
MODUle 1 | Pharmacotherapy (minocycline) activation through TnF-α in 
nF-κB signaling pathway.
dx(1) = kprod-kdeg*x(1) − TN*r1*x(1) % neutral IKK
dx(2) = TN*r1*x(1) − r3*x(2) − TN*r2*x(2)*x(8) 
− kdeg*x(2) − a2*x(2)*x(10) + t1*x(4) − 
a3*x(2)*x(13) + t2*x(5)
% free active IKK
dx(3) = r3*x(2) + TN*r2*x(2)*x(8) − kdeg*x(3) % inactive IKK
dx(4) = a2*x(2)*x(10) − t1*x(4) % cytoplasmic (IKK|IkBa) 
complex
dx(5) = a3*x(2)*x(13) − t2*x(5) % cytoplasmic (IKK|IkBa|NFkB) 
complex
dx(6) = c6a*x(13) − a1*x(6)*x(10) + t2*x(5) −  
i1*x(6)
% Free cytoplasmic NFkB
dx(7) = i1*kv*x(6) − a1*x(11)*x(7) % Free nuclear NFkB
dx(8) = c4*x(9) − c5*x(8) % Cytoplasmic PTGS2 gene
dx(9) = c2 + c1*x(7) − c3*x(9) % PTGS2 transcription
dx(10) = -a2*x(2)*y(10) − a1*x(10)*x(6) + 
c4a*x(12) − c5a*x(10) − i1a*x(10) + e1a*x(11)
% Free cytoplasmic IkBa
dx(11) = -a1*x(11)*x(7) + i1a*kv*x(10) −  
e1a*kv*x(11)
% Free nuclear IkBan
dx(12) = c2a + c1a*x(7) − c3a*x(12) % IkB transcription
dx(13) = a1*x(10)*x(6) − c6a*x(13) − 
a3*x(2)*x(13) + e2a*x(14)
% Cytoplasmic(IkBa|NFkB) 
complex
dx(14) = a1*x(11)*x(7) − e2a*kv*x(14) % Nuclear (IkBa|NFkB) complex
dx(15) = c2c + c1c*x(7) − c3c*x(15) % Control gene mRNA level
MODUle 2 | We now formulate the ordinary differential equations for the 
above chemical reactions (eqs 1–37).
1. dy(1) = k1f* dy(1)*BD + k1f* dy(2)*BD − k1b* dy(3)
2. dy(2) = k2f* dy(3) + k2f* dy(2)*TR − k2b* dy(3)
3. dy(3) = k3f* dy(3) − k3b* dy(4)
4. dy(4) = k4f* dy(4) − k4b* dy(5)
5. dy(5) = k5f* dy(5) − k5b* dy(2)
6. dy(6) = k6f* dy(6) + k6f* dy(4) − k6b* dy(4) + dy(7)
7. dy(7) = k7f* dy(7)-k7b* dy(6)
8. dy(8) = k8f* dy(8) + dy(4) − k8b* dy(4) -k8b* dy(10)
(Continued)
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9. dy(9) = k9f* dy(8) + k9f* dy(9)- k9b *dy(9) − k9b *dy(10)
10. dy(10) = k10f* dy(10) − k10b* dy(8)
11. dy(11) = k11f* dy(11) + k11f* dy(7) − k11b* dy(12)
12. dy(12) = k12f* dy(12) − k12b* dy(13)
13. dy(13) = k13f* dy(13) + k13f* dy(17) − k13b* dy(13)
14. dy(14) = k14f* dy(14) + k14f* dy(17) − k14b* dy(14) 
15. dy(15) = k15f* dy(15) + k15f* dy(13) − k15b* dy(13) − k15b* dy(16)
16. dy(16) = k16f* dy(16) + k16f* PTEN − k16b* PTEN − k16b* dy(15)
17. dy(17) = k17f* d(17) − k17b* PI3K_basal
18. dy(18) = k18f* dy(15) + k18f* PI3K_basal − k18b* PI3K_basal
19. dy(19) = k19f* dy(16) + k19f* dy(19) − k19b* dy(19)
20. dy(20) = k20f * dy(16) + k20f* dy(20) − k20b* dy(21)
21. dy(21) = k21f* dy(20) + k21f* dy(19) − k21b* dy(19) − k21b* dy(22)
22. dy(22) = k22f* dy(22) + k22f* PP2A − k22b* PP2A -k22b* dy(21)
23. dy(23) = k23f* dy(22) + k23f* PIP3_PDK2 − k23b* PIP3_PDK2 − k23b* 
dy(24)
24. dy(24) = k24f* dy(24) + PP2A − k24b* dy(22) − k24b* PP2A
25. dy(25) = k25f* dy(25) + k25f * dy(24) − k25b* dy(24) − k25b* dy(26)
26. dy(26) = k26f* dy(26) − k26b* dy(25)
27. dy(27) = k27f* dy(27) + k27f * dy(25) − k27b* dy(25) − k27b* dy(28)
28. dy(28) = k28f* dy(28) – k28b* dy(28)
29. dy(29) = k29f* dy(29) + k29f*IP3 − k29b* dy(30)
30. dy(30) = k30f* dy(30) + k30f*IP3 − k30b* dy(31)
31. dy(31) = k31f* dy(31) + k31f*IP3 − k31b* dy(32)
32. dy(32) = k32f* dy(32) + k32f*Ca − k32b* dy(32) − k32b*Cacyt
33. dy(33) = k33f* dy(33) + k33f* dy(36) − k37b* dy(34)
34. dy(34) = k34f* dy(34) + k34f* eEF2 − k34b* dy(335) − k334b* dy(34)
35. dy(35) = k35f* dy(35) + k35f* PP2A − k35b* eEF2 − k35b* PP2A
36. dy(36) = k36f* dy(36) + k36f* S6K_thr − k36b* dy(37) −  
k36b* S6K_thr
37. dy(37) = k37f* dy(36) + k37f* S6K_Basal − k37b* dy(36) −  
k37b* S6K_thr
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